Twitter Inc (NYSE:TWTR) announced its move into selling books – a business that built Amazon.com, Inc. (NASDAQ:AMZN) into a formidable tech empire. Twitter Inc (NYSE:TWTR) in last trading activity increased 2.09% to close at $37.05. Company weekly performance is -4.78% while its quarterly performance stands at -29.98%. Twitter Inc (NYSE:TWTR) is -50.42% away from its 52 week high.
EOG Resources, Inc. (NYSE:EOG) announced the divestiture of all its assets in Manitoba and certain assets in Alberta in two separate transactions. On last trading day EOG Resources, Inc. (NYSE:EOG) increased 1.09% to close at $89.15. Its volatility for the week is 3.30% while volatility for the month is 3.00%. EOG’s sales growth for past 5 years was 15.30% and its EPS growth for past 5 years was -3.70%. EOG Resources, Inc. (NYSE:EOG) monthly performance is -10.45%.
Natural Resource Partners LP (NYSE:NRP) Director Corbin J. Robertson III purchased 50,000 shares of the stock on the open market in a transaction that occurred on Monday, December 8th. The stock was purchased at an average price of $9.98 per share, for a total transaction of $499,000.00. On last trading day Natural Resource Partners LP (NYSE:NRP) increased 1.30% to close at $10.15. Its volatility for the week is 4.78% while volatility for the month is 4.93%. NRP’s sales growth for past 5 years was 4.20% and its EPS growth for past 5 years was -4.70%. Natural Resource Partners LP (NYSE:NRP) monthly performance is -20.89%.
Quanta Services, Inc (NYSE:PWR) was downgraded by investment analysts at BB&T Corp. from a “buy” rating to a “hold” rating in a note issued to investors on Monday. Quanta Services, Inc. (NYSE:PWR) has 1.08% insider ownership while its institutional ownership stands at 90.40%. In last trading activity company’s stock closed at $29.74.
On 13 November Cerulean Pharma Inc. (NASDAQ:CERU) launched an important randomized Phase 2 trial in the third quarter,” said Paul A. Friedman, M.D., Executive Chairman of Cerulean. “We are studying the combination of CRLX101 and Avastin® (bevacizumab) versus standard of care in 3rd and 4th line renal cell carcinoma, or RCC. The randomized trial follows provocative Clinical Proof of Principle data from a single-arm investigator-sponsored trial, or IST, where investigators observed a 27% objective response rate, or ORR, in the first 11 patients evaluated in that study. On Tuesday shares of Cerulean Pharma Inc. (NASDAQ:CERU) closed at $5.26.